English
简体中文
Total: £ 56.28
Published Date: 2025-12-04 | Pages: 110 | Tables: 110 | Pharma & Healthcare
The global market for Olopatadine was valued at US$ 627 million in the year 2024 and is projected to reach a revised size of US$ 835 million by 2031, growing at a CAGR of 4.3% during the forecast period.
The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on Olopatadine competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.
In 2024, the global production of olopatadine was 89.5 million units, with an average price of $7 per unit.
Olopatadine is a drug that exerts its anti-allergic effect primarily by blocking histamine H1 receptors. It can be used to treat allergic diseases such as allergic rhinitis, urticaria, pruritus, and allergic conjunctivitis. It is both a selective histamine H1 receptor antagonist and a mast cell stabilizer, capable of inhibiting the release and infiltration of histamine, chemical mediators, and eosinophils.
Olopatadine is a second-generation antihistamine. Its upstream supply chain mainly consists of active pharmaceutical ingredient manufacturers, fine chemical raw material companies, excipient suppliers, and packaging material companies, with raw material costs accounting for a significant proportion of the overall cost. Downstream demand is concentrated in pharmaceutical manufacturers, hospital channels, retail pharmacies, e-commerce platforms, and patients with allergies. Hospitals and chain pharmacies are the core consumer channels, particularly with continuously growing demand from patients with seasonal rhinitis, allergic conjunctivitis, and chronic allergies. Prescriptions show a clear preference for antihistamines with lower safety and side effects, thus olopatadine maintains a high clinical usage frequency in ophthalmic formulations, oral formulations, and nasal sprays. In retail channels, OTC demand is growing significantly, with consumers paying more attention to onset speed, drowsiness, ease of use, and price sensitivity, driving companies to continuously invest in dosage form diversification and branding.
The industry trend is mainly reflected in the iteration of antihistamines towards higher safety, longer duration of action, and more precise targeting. Olopatadine continues to maintain stable growth in the ophthalmology and rhinology fields, especially with significant demand increases in the Asian and Latin American markets. The driving factors include rising seasonal allergy rates, changes in urban air quality, improved accessibility to healthcare, expansion of the OTC anti-allergy market, and the promotion of standardized treatment for ophthalmic and otolaryngological medications. The hindering factors include increased competition from generic drugs due to expiring patents, increased price competition from similar drugs such as loratadine and ebastine, cost control measures implemented by some countries' health insurance programs that compress end-market prices, and unstable costs due to fluctuations in the raw material supply cycle, all of which squeeze corporate profitability.
A standard olopatadine tablet production line typically has an annual output of 120 million–200 million tablets, while an eye drop or nasal spray production line has an annual output of 8 million–15 million bottles. The gross profit margin for tablets is typically 32%–45%, while that for eye drops is mostly 38%–55%.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Olopatadine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Olopatadine.
The Olopatadine market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Olopatadine market comprehensively. Regional market sizes, concerning products by Type, by Application, by Chemical Structure and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Olopatadine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, by Chemical Structure and by regions.
By Company
Alcon Inc.
Novartis AG
Bausch & Lomb Incorporated
Bausch Health Companies Inc.
Santen Pharmaceutical Co., Ltd.
Kyowa Kirin Co., Ltd. (Kyowa Hakko Kogyo)
Teva Pharmaceutical Industries Ltd.
Mylan N.V. (Viatris Inc.)
Hikma Pharmaceuticals PLC
Dr. Reddy’s Laboratories
Sun Pharmaceutical Industries Ltd.
Lupin Limited
Alembic Pharmaceuticals Limited
Glenmark
Aurobindo Pharma Limited
Cipla Limited
Zydus Cadila
Apotex Inc.
Fresenius Kabi AG
Ajanta Pharma Limited
Gland Pharma Limited
Segment by Type
Oral Preparations
Topical Preparations
Ophthalmic Preparations
Segment by Chemical Structure
Olopatadine Hydrochloride
Olopatadine Fumarate
Free Base Form
Segment by Population
Adults
Children (2-11 Years Old)
Seniors (over 65 Years Old)
Segment by Optical Isomers
Racemate (DL-Type)
Single Isomer (R-Type)
Segment by Application
Hospitals
Clinics
Pharmacies
Others
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East and Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Olopatadine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Olopatadine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Olopatadine Market Overview
1.1 Product Definition
1.2 Olopatadine by Type
1.2.1 Global Olopatadine Market Value Comparison by Type (2024 VS 2031)
1.2.2 Oral Preparations
1.2.3 Topical Preparations
1.2.4 Ophthalmic Preparations
1.3 Olopatadine by Chemical Structure
1.3.1 Global Olopatadine Market Value Comparison by Chemical Structure: 2024 VS 2031
1.3.2 Olopatadine Hydrochloride
1.3.3 Olopatadine Fumarate
1.3.4 Free Base Form
1.4 Olopatadine by Population
1.4.1 Global Olopatadine Market Value Comparison by Population: 2024 VS 2031
1.4.2 Adults
1.4.3 Children (2-11 Years Old)
1.4.4 Seniors (over 65 Years Old)
1.5 Olopatadine by Optical Isomers
1.5.1 Global Olopatadine Market Value Comparison by Optical Isomers: 2024 VS 2031
1.5.2 Racemate (DL-Type)
1.5.3 Single Isomer (R-Type)
1.6 Olopatadine by Application
1.6.1 Global Olopatadine Market Value by Application (2024 VS 2031)
1.6.2 Hospitals
1.6.3 Clinics
1.6.4 Pharmacies
1.6.5 Others
1.7 Global Olopatadine Market Size Estimates and Forecasts
1.7.1 Global Olopatadine Revenue 2020-2031
1.7.2 Global Olopatadine Sales 2020-2031
1.7.3 Global Olopatadine Market Average Price (2020-2031)
1.8 Assumptions and Limitations
2 Olopatadine Market Competition by Manufacturers
2.1 Global Olopatadine Sales Market Share by Manufacturers (2020-2025)
2.2 Global Olopatadine Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Olopatadine Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Olopatadine, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Olopatadine, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Olopatadine, Product Type & Application
2.7 Global Key Manufacturers of Olopatadine, Date of Enter into This Industry
2.8 Global Olopatadine Market Competitive Situation and Trends
2.8.1 Global Olopatadine Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Olopatadine Players Market Share by Revenue
2.8.3 Global Olopatadine Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Olopatadine Market Scenario by Region
3.1 Global Olopatadine Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Olopatadine Sales by Region: 2020-2031
3.2.1 Global Olopatadine Sales by Region: 2020-2025
3.2.2 Global Olopatadine Sales by Region: 2026-2031
3.3 Global Olopatadine Revenue by Region: 2020-2031
3.3.1 Global Olopatadine Revenue by Region: 2020-2025
3.3.2 Global Olopatadine Revenue by Region: 2026-2031
3.4 North America Olopatadine Market Facts & Figures by Country
3.4.1 North America Olopatadine Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Olopatadine Sales by Country (2020-2031)
3.4.3 North America Olopatadine Revenue by Country (2020-2031)
3.4.4 United States
3.4.5 Canada
3.5 Europe Olopatadine Market Facts & Figures by Country
3.5.1 Europe Olopatadine Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Olopatadine Sales by Country (2020-2031)
3.5.3 Europe Olopatadine Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Olopatadine Market Facts & Figures by Region
3.6.1 Asia Pacific Olopatadine Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Olopatadine Sales by Region (2020-2031)
3.6.3 Asia Pacific Olopatadine Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Olopatadine Market Facts & Figures by Country
3.7.1 Latin America Olopatadine Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Olopatadine Sales by Country (2020-2031)
3.7.3 Latin America Olopatadine Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Olopatadine Market Facts & Figures by Country
3.8.1 Middle East and Africa Olopatadine Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Olopatadine Sales by Country (2020-2031)
3.8.3 Middle East and Africa Olopatadine Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Olopatadine Sales by Type (2020-2031)
4.1.1 Global Olopatadine Sales by Type (2020-2025)
4.1.2 Global Olopatadine Sales by Type (2026-2031)
4.1.3 Global Olopatadine Sales Market Share by Type (2020-2031)
4.2 Global Olopatadine Revenue by Type (2020-2031)
4.2.1 Global Olopatadine Revenue by Type (2020-2025)
4.2.2 Global Olopatadine Revenue by Type (2026-2031)
4.2.3 Global Olopatadine Revenue Market Share by Type (2020-2031)
4.3 Global Olopatadine Price by Type (2020-2031)
5 Segment by Application
5.1 Global Olopatadine Sales by Application (2020-2031)
5.1.1 Global Olopatadine Sales by Application (2020-2025)
5.1.2 Global Olopatadine Sales by Application (2026-2031)
5.1.3 Global Olopatadine Sales Market Share by Application (2020-2031)
5.2 Global Olopatadine Revenue by Application (2020-2031)
5.2.1 Global Olopatadine Revenue by Application (2020-2025)
5.2.2 Global Olopatadine Revenue by Application (2026-2031)
5.2.3 Global Olopatadine Revenue Market Share by Application (2020-2031)
5.3 Global Olopatadine Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Alcon Inc.
6.1.1 Alcon Inc. Company Information
6.1.2 Alcon Inc. Description and Business Overview
6.1.3 Alcon Inc. Olopatadine Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Alcon Inc. Olopatadine Product Portfolio
6.1.5 Alcon Inc. Recent Developments/Updates
6.2 Novartis AG
6.2.1 Novartis AG Company Information
6.2.2 Novartis AG Description and Business Overview
6.2.3 Novartis AG Olopatadine Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Novartis AG Olopatadine Product Portfolio
6.2.5 Novartis AG Recent Developments/Updates
6.3 Bausch & Lomb Incorporated
6.3.1 Bausch & Lomb Incorporated Company Information
6.3.2 Bausch & Lomb Incorporated Description and Business Overview
6.3.3 Bausch & Lomb Incorporated Olopatadine Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Bausch & Lomb Incorporated Olopatadine Product Portfolio
6.3.5 Bausch & Lomb Incorporated Recent Developments/Updates
6.4 Bausch Health Companies Inc.
6.4.1 Bausch Health Companies Inc. Company Information
6.4.2 Bausch Health Companies Inc. Description and Business Overview
6.4.3 Bausch Health Companies Inc. Olopatadine Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Bausch Health Companies Inc. Olopatadine Product Portfolio
6.4.5 Bausch Health Companies Inc. Recent Developments/Updates
6.5 Santen Pharmaceutical Co., Ltd.
6.5.1 Santen Pharmaceutical Co., Ltd. Company Information
6.5.2 Santen Pharmaceutical Co., Ltd. Description and Business Overview
6.5.3 Santen Pharmaceutical Co., Ltd. Olopatadine Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Santen Pharmaceutical Co., Ltd. Olopatadine Product Portfolio
6.5.5 Santen Pharmaceutical Co., Ltd. Recent Developments/Updates
6.6 Kyowa Kirin Co., Ltd. (Kyowa Hakko Kogyo)
6.6.1 Kyowa Kirin Co., Ltd. (Kyowa Hakko Kogyo) Company Information
6.6.2 Kyowa Kirin Co., Ltd. (Kyowa Hakko Kogyo) Description and Business Overview
6.6.3 Kyowa Kirin Co., Ltd. (Kyowa Hakko Kogyo) Olopatadine Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Kyowa Kirin Co., Ltd. (Kyowa Hakko Kogyo) Olopatadine Product Portfolio
6.6.5 Kyowa Kirin Co., Ltd. (Kyowa Hakko Kogyo) Recent Developments/Updates
6.7 Teva Pharmaceutical Industries Ltd.
6.7.1 Teva Pharmaceutical Industries Ltd. Company Information
6.7.2 Teva Pharmaceutical Industries Ltd. Description and Business Overview
6.7.3 Teva Pharmaceutical Industries Ltd. Olopatadine Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Teva Pharmaceutical Industries Ltd. Olopatadine Product Portfolio
6.7.5 Teva Pharmaceutical Industries Ltd. Recent Developments/Updates
6.8 Mylan N.V. (Viatris Inc.)
6.8.1 Mylan N.V. (Viatris Inc.) Company Information
6.8.2 Mylan N.V. (Viatris Inc.) Description and Business Overview
6.8.3 Mylan N.V. (Viatris Inc.) Olopatadine Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Mylan N.V. (Viatris Inc.) Olopatadine Product Portfolio
6.8.5 Mylan N.V. (Viatris Inc.) Recent Developments/Updates
6.9 Hikma Pharmaceuticals PLC
6.9.1 Hikma Pharmaceuticals PLC Company Information
6.9.2 Hikma Pharmaceuticals PLC Description and Business Overview
6.9.3 Hikma Pharmaceuticals PLC Olopatadine Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Hikma Pharmaceuticals PLC Olopatadine Product Portfolio
6.9.5 Hikma Pharmaceuticals PLC Recent Developments/Updates
6.10 Dr. Reddy’s Laboratories
6.10.1 Dr. Reddy’s Laboratories Company Information
6.10.2 Dr. Reddy’s Laboratories Description and Business Overview
6.10.3 Dr. Reddy’s Laboratories Olopatadine Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Dr. Reddy’s Laboratories Olopatadine Product Portfolio
6.10.5 Dr. Reddy’s Laboratories Recent Developments/Updates
6.11 Sun Pharmaceutical Industries Ltd.
6.11.1 Sun Pharmaceutical Industries Ltd. Company Information
6.11.2 Sun Pharmaceutical Industries Ltd. Description and Business Overview
6.11.3 Sun Pharmaceutical Industries Ltd. Olopatadine Sales, Revenue and Gross Margin (2020-2025)
6.11.4 Sun Pharmaceutical Industries Ltd. Olopatadine Product Portfolio
6.11.5 Sun Pharmaceutical Industries Ltd. Recent Developments/Updates
6.12 Lupin Limited
6.12.1 Lupin Limited Company Information
6.12.2 Lupin Limited Description and Business Overview
6.12.3 Lupin Limited Olopatadine Sales, Revenue and Gross Margin (2020-2025)
6.12.4 Lupin Limited Olopatadine Product Portfolio
6.12.5 Lupin Limited Recent Developments/Updates
6.13 Alembic Pharmaceuticals Limited
6.13.1 Alembic Pharmaceuticals Limited Company Information
6.13.2 Alembic Pharmaceuticals Limited Description and Business Overview
6.13.3 Alembic Pharmaceuticals Limited Olopatadine Sales, Revenue and Gross Margin (2020-2025)
6.13.4 Alembic Pharmaceuticals Limited Olopatadine Product Portfolio
6.13.5 Alembic Pharmaceuticals Limited Recent Developments/Updates
6.14 Glenmark
6.14.1 Glenmark Company Information
6.14.2 Glenmark Description and Business Overview
6.14.3 Glenmark Olopatadine Sales, Revenue and Gross Margin (2020-2025)
6.14.4 Glenmark Olopatadine Product Portfolio
6.14.5 Glenmark Recent Developments/Updates
6.15 Aurobindo Pharma Limited
6.15.1 Aurobindo Pharma Limited Company Information
6.15.2 Aurobindo Pharma Limited Description and Business Overview
6.15.3 Aurobindo Pharma Limited Olopatadine Sales, Revenue and Gross Margin (2020-2025)
6.15.4 Aurobindo Pharma Limited Olopatadine Product Portfolio
6.15.5 Aurobindo Pharma Limited Recent Developments/Updates
6.16 Cipla Limited
6.16.1 Cipla Limited Company Information
6.16.2 Cipla Limited Description and Business Overview
6.16.3 Cipla Limited Olopatadine Sales, Revenue and Gross Margin (2020-2025)
6.16.4 Cipla Limited Olopatadine Product Portfolio
6.16.5 Cipla Limited Recent Developments/Updates
6.17 Zydus Cadila
6.17.1 Zydus Cadila Company Information
6.17.2 Zydus Cadila Description and Business Overview
6.17.3 Zydus Cadila Olopatadine Sales, Revenue and Gross Margin (2020-2025)
6.17.4 Zydus Cadila Olopatadine Product Portfolio
6.17.5 Zydus Cadila Recent Developments/Updates
6.18 Apotex Inc.
6.18.1 Apotex Inc. Company Information
6.18.2 Apotex Inc. Description and Business Overview
6.18.3 Apotex Inc. Olopatadine Sales, Revenue and Gross Margin (2020-2025)
6.18.4 Apotex Inc. Olopatadine Product Portfolio
6.18.5 Apotex Inc. Recent Developments/Updates
6.19 Fresenius Kabi AG
6.19.1 Fresenius Kabi AG Company Information
6.19.2 Fresenius Kabi AG Description and Business Overview
6.19.3 Fresenius Kabi AG Olopatadine Sales, Revenue and Gross Margin (2020-2025)
6.19.4 Fresenius Kabi AG Olopatadine Product Portfolio
6.19.5 Fresenius Kabi AG Recent Developments/Updates
6.20 Ajanta Pharma Limited
6.20.1 Ajanta Pharma Limited Company Information
6.20.2 Ajanta Pharma Limited Description and Business Overview
6.20.3 Ajanta Pharma Limited Olopatadine Sales, Revenue and Gross Margin (2020-2025)
6.20.4 Ajanta Pharma Limited Olopatadine Product Portfolio
6.20.5 Ajanta Pharma Limited Recent Developments/Updates
6.21 Gland Pharma Limited
6.21.1 Gland Pharma Limited Company Information
6.21.2 Gland Pharma Limited Description and Business Overview
6.21.3 Gland Pharma Limited Olopatadine Sales, Revenue and Gross Margin (2020-2025)
6.21.4 Gland Pharma Limited Olopatadine Product Portfolio
6.21.5 Gland Pharma Limited Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Olopatadine Industry Chain Analysis
7.2 Olopatadine Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Olopatadine Production Mode & Process Analysis
7.4 Olopatadine Sales and Marketing
7.4.1 Olopatadine Sales Channels
7.4.2 Olopatadine Distributors
7.5 Olopatadine Customer Analysis
8 Olopatadine Market Dynamics
8.1 Olopatadine Industry Trends
8.2 Olopatadine Market Drivers
8.3 Olopatadine Market Challenges
8.4 Olopatadine Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
Table 1. Global Olopatadine Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
Table 2. Global Olopatadine Market Value by Chemical Structure, (US$ Million) & (2024 VS 2031)
Table 3. Global Olopatadine Market Value by Population, (US$ Million) & (2024 VS 2031)
Table 4. Global Olopatadine Market Value by Optical Isomers, (US$ Million) & (2024 VS 2031)
Table 5. Global Olopatadine Market Value by Application (2024 VS 2031) & (US$ Million)
Table 6. Global Olopatadine Market Competitive Situation by Manufacturers in 2024
Table 7. Global Olopatadine Sales (K Units) of Key Manufacturers (2020-2025)
Table 8. Global Olopatadine Sales Market Share by Manufacturers (2020-2025)
Table 9. Global Olopatadine Revenue (US$ Million) by Manufacturers (2020-2025)
Table 10. Global Olopatadine Revenue Share by Manufacturers (2020-2025)
Table 11. Global Market Olopatadine Average Price (US$/Unit) of Key Manufacturers (2020-2025)
Table 12. Global Key Players of Olopatadine, Industry Ranking, 2022 VS 2023 VS 2024
Table 13. Global Key Manufacturers of Olopatadine, Manufacturing Sites & Headquarters
Table 14. Global Key Manufacturers of Olopatadine, Product Type & Application
Table 15. Global Key Manufacturers of Olopatadine, Date of Enter into This Industry
Table 16. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 17. Global Olopatadine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Olopatadine as of 2024)
Table 18. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 19. Global Olopatadine Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 20. Global Olopatadine Sales by Region (2020-2025) & (K Units)
Table 21. Global Olopatadine Sales Market Share by Region (2020-2025)
Table 22. Global Olopatadine Sales by Region (2026-2031) & (K Units)
Table 23. Global Olopatadine Sales Market Share by Region (2026-2031)
Table 24. Global Olopatadine Revenue by Region (2020-2025) & (US$ Million)
Table 25. Global Olopatadine Revenue Market Share by Region (2020-2025)
Table 26. Global Olopatadine Revenue by Region (2026-2031) & (US$ Million)
Table 27. Global Olopatadine Revenue Market Share by Region (2026-2031)
Table 28. North America Olopatadine Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 29. North America Olopatadine Sales by Country (2020-2025) & (K Units)
Table 30. North America Olopatadine Sales by Country (2026-2031) & (K Units)
Table 31. North America Olopatadine Revenue by Country (2020-2025) & (US$ Million)
Table 32. North America Olopatadine Revenue by Country (2026-2031) & (US$ Million)
Table 33. Europe Olopatadine Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 34. Europe Olopatadine Sales by Country (2020-2025) & (K Units)
Table 35. Europe Olopatadine Sales by Country (2026-2031) & (K Units)
Table 36. Europe Olopatadine Revenue by Country (2020-2025) & (US$ Million)
Table 37. Europe Olopatadine Revenue by Country (2026-2031) & (US$ Million)
Table 38. Asia Pacific Olopatadine Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 39. Asia Pacific Olopatadine Sales by Region (2020-2025) & (K Units)
Table 40. Asia Pacific Olopatadine Sales by Region (2026-2031) & (K Units)
Table 41. Asia Pacific Olopatadine Revenue by Region (2020-2025) & (US$ Million)
Table 42. Asia Pacific Olopatadine Revenue by Region (2026-2031) & (US$ Million)
Table 43. Latin America Olopatadine Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 44. Latin America Olopatadine Sales by Country (2020-2025) & (K Units)
Table 45. Latin America Olopatadine Sales by Country (2026-2031) & (K Units)
Table 46. Latin America Olopatadine Revenue by Country (2020-2025) & (US$ Million)
Table 47. Latin America Olopatadine Revenue by Country (2026-2031) & (US$ Million)
Table 48. Middle East and Africa Olopatadine Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 49. Middle East and Africa Olopatadine Sales by Country (2020-2025) & (K Units)
Table 50. Middle East and Africa Olopatadine Sales by Country (2026-2031) & (K Units)
Table 51. Middle East and Africa Olopatadine Revenue by Country (2020-2025) & (US$ Million)
Table 52. Middle East and Africa Olopatadine Revenue by Country (2026-2031) & (US$ Million)
Table 53. Global Olopatadine Sales (K Units) by Type (2020-2025)
Table 54. Global Olopatadine Sales (K Units) by Type (2026-2031)
Table 55. Global Olopatadine Sales Market Share by Type (2020-2025)
Table 56. Global Olopatadine Sales Market Share by Type (2026-2031)
Table 57. Global Olopatadine Revenue (US$ Million) by Type (2020-2025)
Table 58. Global Olopatadine Revenue (US$ Million) by Type (2026-2031)
Table 59. Global Olopatadine Revenue Market Share by Type (2020-2025)
Table 60. Global Olopatadine Revenue Market Share by Type (2026-2031)
Table 61. Global Olopatadine Price (US$/Unit) by Type (2020-2025)
Table 62. Global Olopatadine Price (US$/Unit) by Type (2026-2031)
Table 63. Global Olopatadine Sales (K Units) by Application (2020-2025)
Table 64. Global Olopatadine Sales (K Units) by Application (2026-2031)
Table 65. Global Olopatadine Sales Market Share by Application (2020-2025)
Table 66. Global Olopatadine Sales Market Share by Application (2026-2031)
Table 67. Global Olopatadine Revenue (US$ Million) by Application (2020-2025)
Table 68. Global Olopatadine Revenue (US$ Million) by Application (2026-2031)
Table 69. Global Olopatadine Revenue Market Share by Application (2020-2025)
Table 70. Global Olopatadine Revenue Market Share by Application (2026-2031)
Table 71. Global Olopatadine Price (US$/Unit) by Application (2020-2025)
Table 72. Global Olopatadine Price (US$/Unit) by Application (2026-2031)
Table 73. Alcon Inc. Company Information
Table 74. Alcon Inc. Description and Business Overview
Table 75. Alcon Inc. Olopatadine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 76. Alcon Inc. Olopatadine Product
Table 77. Alcon Inc. Recent Developments/Updates
Table 78. Novartis AG Company Information
Table 79. Novartis AG Description and Business Overview
Table 80. Novartis AG Olopatadine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 81. Novartis AG Olopatadine Product
Table 82. Novartis AG Recent Developments/Updates
Table 83. Bausch & Lomb Incorporated Company Information
Table 84. Bausch & Lomb Incorporated Description and Business Overview
Table 85. Bausch & Lomb Incorporated Olopatadine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 86. Bausch & Lomb Incorporated Olopatadine Product
Table 87. Bausch & Lomb Incorporated Recent Developments/Updates
Table 88. Bausch Health Companies Inc. Company Information
Table 89. Bausch Health Companies Inc. Description and Business Overview
Table 90. Bausch Health Companies Inc. Olopatadine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 91. Bausch Health Companies Inc. Olopatadine Product
Table 92. Bausch Health Companies Inc. Recent Developments/Updates
Table 93. Santen Pharmaceutical Co., Ltd. Company Information
Table 94. Santen Pharmaceutical Co., Ltd. Description and Business Overview
Table 95. Santen Pharmaceutical Co., Ltd. Olopatadine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 96. Santen Pharmaceutical Co., Ltd. Olopatadine Product
Table 97. Santen Pharmaceutical Co., Ltd. Recent Developments/Updates
Table 98. Kyowa Kirin Co., Ltd. (Kyowa Hakko Kogyo) Company Information
Table 99. Kyowa Kirin Co., Ltd. (Kyowa Hakko Kogyo) Description and Business Overview
Table 100. Kyowa Kirin Co., Ltd. (Kyowa Hakko Kogyo) Olopatadine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 101. Kyowa Kirin Co., Ltd. (Kyowa Hakko Kogyo) Olopatadine Product
Table 102. Kyowa Kirin Co., Ltd. (Kyowa Hakko Kogyo) Recent Developments/Updates
Table 103. Teva Pharmaceutical Industries Ltd. Company Information
Table 104. Teva Pharmaceutical Industries Ltd. Description and Business Overview
Table 105. Teva Pharmaceutical Industries Ltd. Olopatadine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 106. Teva Pharmaceutical Industries Ltd. Olopatadine Product
Table 107. Teva Pharmaceutical Industries Ltd. Recent Developments/Updates
Table 108. Mylan N.V. (Viatris Inc.) Company Information
Table 109. Mylan N.V. (Viatris Inc.) Description and Business Overview
Table 110. Mylan N.V. (Viatris Inc.) Olopatadine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 111. Mylan N.V. (Viatris Inc.) Olopatadine Product
Table 112. Mylan N.V. (Viatris Inc.) Recent Developments/Updates
Table 113. Hikma Pharmaceuticals PLC Company Information
Table 114. Hikma Pharmaceuticals PLC Description and Business Overview
Table 115. Hikma Pharmaceuticals PLC Olopatadine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 116. Hikma Pharmaceuticals PLC Olopatadine Product
Table 117. Hikma Pharmaceuticals PLC Recent Developments/Updates
Table 118. Dr. Reddy’s Laboratories Company Information
Table 119. Dr. Reddy’s Laboratories Description and Business Overview
Table 120. Dr. Reddy’s Laboratories Olopatadine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 121. Dr. Reddy’s Laboratories Olopatadine Product
Table 122. Dr. Reddy’s Laboratories Recent Developments/Updates
Table 123. Sun Pharmaceutical Industries Ltd. Company Information
Table 124. Sun Pharmaceutical Industries Ltd. Description and Business Overview
Table 125. Sun Pharmaceutical Industries Ltd. Olopatadine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 126. Sun Pharmaceutical Industries Ltd. Olopatadine Product
Table 127. Sun Pharmaceutical Industries Ltd. Recent Developments/Updates
Table 128. Lupin Limited Company Information
Table 129. Lupin Limited Description and Business Overview
Table 130. Lupin Limited Olopatadine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 131. Lupin Limited Olopatadine Product
Table 132. Lupin Limited Recent Developments/Updates
Table 133. Alembic Pharmaceuticals Limited Company Information
Table 134. Alembic Pharmaceuticals Limited Description and Business Overview
Table 135. Alembic Pharmaceuticals Limited Olopatadine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 136. Alembic Pharmaceuticals Limited Olopatadine Product
Table 137. Alembic Pharmaceuticals Limited Recent Developments/Updates
Table 138. Glenmark Company Information
Table 139. Glenmark Description and Business Overview
Table 140. Glenmark Olopatadine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 141. Glenmark Olopatadine Product
Table 142. Glenmark Recent Developments/Updates
Table 143. Aurobindo Pharma Limited Company Information
Table 144. Aurobindo Pharma Limited Description and Business Overview
Table 145. Aurobindo Pharma Limited Olopatadine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 146. Aurobindo Pharma Limited Olopatadine Product
Table 147. Aurobindo Pharma Limited Recent Developments/Updates
Table 148. Cipla Limited Company Information
Table 149. Cipla Limited Description and Business Overview
Table 150. Cipla Limited Olopatadine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 151. Cipla Limited Olopatadine Product
Table 152. Cipla Limited Recent Developments/Updates
Table 153. Zydus Cadila Company Information
Table 154. Zydus Cadila Description and Business Overview
Table 155. Zydus Cadila Olopatadine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 156. Zydus Cadila Olopatadine Product
Table 157. Zydus Cadila Recent Developments/Updates
Table 158. Apotex Inc. Company Information
Table 159. Apotex Inc. Description and Business Overview
Table 160. Apotex Inc. Olopatadine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 161. Apotex Inc. Olopatadine Product
Table 162. Apotex Inc. Recent Developments/Updates
Table 163. Fresenius Kabi AG Company Information
Table 164. Fresenius Kabi AG Description and Business Overview
Table 165. Fresenius Kabi AG Olopatadine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 166. Fresenius Kabi AG Olopatadine Product
Table 167. Fresenius Kabi AG Recent Developments/Updates
Table 168. Ajanta Pharma Limited Company Information
Table 169. Ajanta Pharma Limited Description and Business Overview
Table 170. Ajanta Pharma Limited Olopatadine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 171. Ajanta Pharma Limited Olopatadine Product
Table 172. Ajanta Pharma Limited Recent Developments/Updates
Table 173. Gland Pharma Limited Company Information
Table 174. Gland Pharma Limited Description and Business Overview
Table 175. Gland Pharma Limited Olopatadine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 176. Gland Pharma Limited Olopatadine Product
Table 177. Gland Pharma Limited Recent Developments/Updates
Table 178. Key Raw Materials Lists
Table 179. Raw Materials Key Suppliers Lists
Table 180. Olopatadine Distributors List
Table 181. Olopatadine Customers List
Table 182. Olopatadine Market Trends
Table 183. Olopatadine Market Drivers
Table 184. Olopatadine Market Challenges
Table 185. Olopatadine Market Restraints
Table 186. Research Programs/Design for This Report
Table 187. Key Data Information from Secondary Sources
Table 188. Key Data Information from Primary Sources
Table 189. Authors List of This Report
List of Figures
Figure 1. Product Picture of Olopatadine
Figure 2. Global Olopatadine Market Value Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Olopatadine Market Share by Type: 2024 & 2031
Figure 4. Oral Preparations Product Picture
Figure 5. Topical Preparations Product Picture
Figure 6. Ophthalmic Preparations Product Picture
Figure 7. Global Olopatadine Market Value by Chemical Structure, (US$ Million) & (2020-2031)
Figure 8. Global Olopatadine Market Share by Chemical Structure: 2024 VS 2031
Figure 9. Olopatadine Hydrochloride Product Picture
Figure 10. Olopatadine Fumarate Product Picture
Figure 11. Free Base Form Product Picture
Figure 12. Global Olopatadine Market Value by Population, (US$ Million) & (2020-2031)
Figure 13. Global Olopatadine Market Share by Population: 2024 VS 2031
Figure 14. Adults Product Picture
Figure 15. Children (2-11 Years Old) Product Picture
Figure 16. Seniors (over 65 Years Old) Product Picture
Figure 17. Global Olopatadine Market Value by Optical Isomers, (US$ Million) & (2020-2031)
Figure 18. Global Olopatadine Market Share by Optical Isomers: 2024 VS 2031
Figure 19. Racemate (DL-Type) Product Picture
Figure 20. Single Isomer (R-Type) Product Picture
Figure 21. Global Olopatadine Market Value by Application (2020-2031) & (US$ Million)
Figure 22. Global Olopatadine Market Share by Application: 2024 & 2031
Figure 23. Hospitals
Figure 24. Clinics
Figure 25. Pharmacies
Figure 26. Others
Figure 27. Global Olopatadine Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 28. Global Olopatadine Market Size (2020-2031) & (US$ Million)
Figure 29. Global Olopatadine Sales (2020-2031) & (K Units)
Figure 30. Global Olopatadine Average Price (US$/Unit) & (2020-2031)
Figure 31. Olopatadine Report Years Considered
Figure 32. Olopatadine Sales Share by Manufacturers in 2024
Figure 33. Global Olopatadine Revenue Share by Manufacturers in 2024
Figure 34. Global 5 and 10 Largest Olopatadine Players: Market Share by Revenue in Olopatadine in 2024
Figure 35. Olopatadine Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 36. Global Olopatadine Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Figure 37. North America Olopatadine Sales Market Share by Country (2020-2031)
Figure 38. North America Olopatadine Revenue Market Share by Country (2020-2031)
Figure 39. United States Olopatadine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 40. Canada Olopatadine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 41. Europe Olopatadine Sales Market Share by Country (2020-2031)
Figure 42. Europe Olopatadine Revenue Market Share by Country (2020-2031)
Figure 43. Germany Olopatadine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 44. France Olopatadine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 45. U.K. Olopatadine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 46. Italy Olopatadine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 47. Russia Olopatadine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 48. Asia Pacific Olopatadine Sales Market Share by Region (2020-2031)
Figure 49. Asia Pacific Olopatadine Revenue Market Share by Region (2020-2031)
Figure 50. China Olopatadine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 51. Japan Olopatadine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 52. South Korea Olopatadine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 53. India Olopatadine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 54. Australia Olopatadine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 55. China Taiwan Olopatadine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 56. Southeast Asia Olopatadine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 57. Latin America Olopatadine Sales Market Share by Country (2020-2031)
Figure 58. Latin America Olopatadine Revenue Market Share by Country (2020-2031)
Figure 59. Mexico Olopatadine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 60. Brazil Olopatadine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 61. Argentina Olopatadine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 62. Colombia Olopatadine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 63. Middle East and Africa Olopatadine Sales Market Share by Country (2020-2031)
Figure 64. Middle East and Africa Olopatadine Revenue Market Share by Country (2020-2031)
Figure 65. Turkey Olopatadine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 66. Saudi Arabia Olopatadine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 67. UAE Olopatadine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 68. Global Sales Market Share of Olopatadine by Type (2020-2031)
Figure 69. Global Revenue Market Share of Olopatadine by Type (2020-2031)
Figure 70. Global Olopatadine Price (US$/Unit) by Type (2020-2031)
Figure 71. Global Sales Market Share of Olopatadine by Application (2020-2031)
Figure 72. Global Revenue Market Share of Olopatadine by Application (2020-2031)
Figure 73. Global Olopatadine Price (US$/Unit) by Application (2020-2031)
Figure 74. Olopatadine Value Chain
Figure 75. Channels of Distribution (Direct Vs Distribution)
Figure 76. Bottom-up and Top-down Approaches for This Report
Figure 77. Data Triangulation
Figure 78. Key Executives Interviewed
